JZY3032
JYZ3032 (DALTAC-1) is an orally active super inhibitor of androgen receptor (AR) and p300/CBP. JYZ3032 redirects the catalytic activity of p300 and locks the complex in a transcriptionally inactive state, thereby inhibiting AR-driven transcription and proliferation. JYZ3032 induces deep and durable tumor regression in castration-resistant and patient-derived xenograft models, and exhibits good tolerability. JYZ3032 can be used in research related to metastatic castration-resistant prostate cancer and prostate cancer.
For research use only. We do not sell to patients.
- Formula: C52H62ClF2N13O2
- Molecular Weight:974.58
-
Storage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
|
p300 |
In Vitro
JYZ3032 (100 nM, Serial dilutions; 4 h pulse treatment, total 120 h) exhibits durable, sustained growth inhibitory activity in VCaP and LNCaP prostate cancer cells, with a 4-hour pulse treatment yielding comparable efficacy to continuous exposure[1].
JYZ3032 potently suppresses enhancer-associated histone acetylation marks in VCaP prostate cancer cells but not in AR-negative Kelly neuroblastoma cells, demonstrating lineage selectivity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:22Rv1 prostate cancer cells
-
Concentration:1.0 nM
-
Incubation Time:120 h
-
Result:Inhibited 22Rv1 cell growth with an IC50 of 1.0 nM and a maximum inhibition (Imax) of 69%.
-
Cell Line:VCaP, LNCaP, CWR-R1 prostate cancer cells
-
Concentration:Serial dilutions
-
Incubation Time:120 h
-
Result:Exhibited potent cytotoxicity across all tested AR-positive prostate cancer cells, with superior activity relative to the combined treatment with AR-LBD inhibitor JZY3221 and p300/CBP BRD inhibitor GNE-049.
Activity was comparable to or better than the p300/CBP dual degrader CBPD-409 (HY-158113).
Parmacokinetics
In Vivo
YZ3032 (60 mg/kg; p.o.) also achieves significant tumor inhibition in mice model, with good tolerance[1].
JYZ3032 induces complete tumor regression and 100% survival for at least 35 days in NSG mice bearing patient-derived prostate cancer xenografts of MDA-PCa-183, significantly inhibits tumor growth in the MDA-PCa-146-12 model, and exhibits good tolerance[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG (male, castrated)[1]
-
Dosage:30 mg/kg (i.p.); 60 mg/kg (p.o.)
-
Administration:i.p.; p.o.
-
Result:Induced tumor regression in 75% (12 of 16) of treated tumors.
Achieved robust tumor suppression that outperformed a combination of a p300 bromodomain inhibitor and an AR-LBD inhibitor.
Increased AR-p300 proximity in treated tumors.
Reduced ERG, PSA, MYC, Ki67, H3K27ac, and H2BK20ac signals in treated tumors.
Left AR, p300, and CBP levels unchanged.
Caused no significant changes in body weight, serum liver/kidney function, or hematologic parameters.
- Research Protocol for Endocrine Diseases
- Patient-Derived Xenograft (PDX)
- Patient-Derived Orthotopic Xenograft (PDOX)
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Cell Viability Determination by MTT Colorimetric Assay
- Intraperitoneal/Peritoneal Dissemination Xenograft
Chemical Information
-
Appearance Solid
-
Molecular Weight 974.58
-
Formula C52H62ClF2N13O2
-
Color White to light yellow
-
SMILES
CN1N=CC(C2=CC3=C(N(C4=NN([C@H](CC5)CC[C@@H]5CN(CC6)CCN6C(C=C7)=NN=C7C(N[C@H]8CC[C@@H](CC8)N(C)C9=CC=C(C(Cl)=C9)C#N)=O)C%10=C4CN(C(C)=O)CC%10)CCC3)C=C2C(F)F)=C1
-
Synonyms
DALTAC-1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (102.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0261 mL | 5.1304 mL | 10.2608 mL | 25.6521 mL |
| 5 mM | 0.2052 mL | 1.0261 mL | 2.0522 mL | 5.1304 mL | |
| 10 mM | 0.1026 mL | 0.5130 mL | 1.0261 mL | 2.5652 mL | |
| 15 mM | 0.0684 mL | 0.3420 mL | 0.6841 mL | 1.7101 mL | |
| 20 mM | 0.0513 mL | 0.2565 mL | 0.5130 mL | 1.2826 mL | |
| 25 mM | 0.0410 mL | 0.2052 mL | 0.4104 mL | 1.0261 mL | |
| 30 mM | 0.0342 mL | 0.1710 mL | 0.3420 mL | 0.8551 mL | |
| 40 mM | 0.0257 mL | 0.1283 mL | 0.2565 mL | 0.6413 mL | |
| 50 mM | 0.0205 mL | 0.1026 mL | 0.2052 mL | 0.5130 mL | |
| 60 mM | 0.0171 mL | 0.0855 mL | 0.1710 mL | 0.4275 mL | |
| 80 mM | 0.0128 mL | 0.0641 mL | 0.1283 mL | 0.3207 mL | |
| 100 mM | 0.0103 mL | 0.0513 mL | 0.1026 mL | 0.2565 mL |
JZY3032 Related Classifications
HY-184124 Related Classifications
Powered by Bioz
Keywords
- JZY3032
- DALTAC-1
- JZY 3032
- JZY-3032
- DALTAC1
- DALTAC 1
- Androgen Receptor
- Histone Acetyltransferase
- patient-derived organoids
- HEK293 cells
- p300/CBP
- LNCaP
- metastatic castration-resistant prostate cancer
- AR-positive prostate cancer cells
- 22Rv1
- VCaP
- castration-resistant prostate cancer
- androgen receptor
- Inhibitor
- inhibitor
- inhibit